ReviewDrug design, development and therapy2026
Konjac Glucomannan as a Gel-Forming Biopolymer for Transdermal Drug Delivery: Properties, Formulation Strategies, and Translational Challenges.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Konjac glucomannan is a natural polysaccharide increasingly relevant as a matrix forming material for skin applied delivery systems. Its potential is linked to its glucose and mannose backbone, abundant hydroxyl groups, partial acetyl substitution, high molecular weight, and capacity for chain association. These features regulate hydration, swelling, rheology, viscoelasticity, film formation, gelation, and drug release. This narrative review examines konjac glucomannan from a structure based formulation perspective, covering physicochemical attributes, modification strategies, formulation platforms, release behavior, and evaluation requirements. Unlike previous reviews that broadly discuss polysaccharide based transdermal systems or glucomannan across pharmaceutical applications, this review focuses on the relationship between KGM structure, formulation design, and translational performance. Evidence shows its use in films, hydrogel reservoirs, injectable hydrogels, nanofibrous systems, carrier assisted systems, and multilayer matrices. In these platforms, konjac glucomannan functions as a hydration regulating matrix former, release modulator, and structural component. Blending, deacetylation, oxidation, crosslinking, freeze thaw treatment, electrospinning, and layered design can improve mechanical integrity, moisture control, and release performance. However, outcomes vary with molecular attributes, modification conditions, and evaluation methods. Most studies remain focused on material characterization and in vitro release, while durable skin adhesion, ex vivo permeation, skin deposition, long wear performance, and clinically meaningful transport are still insufficiently demonstrated. Further translation requires standardized molecular attributes, ex vivo and in vivo testing, scalable manufacturing, and regulatory evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.